Updated: Dec 6, 2020
Community mitigation of infectious diseases depends on the rapid deployment of effective diagnostic tools to detect, and novel therapeutic technologies to limit the spread of the infection, whether caused by bacteria, viral, fungal or parasitic infections. With the advent of the coronavirus (COVID-19) and the ensuing pandemic, biomedical research has decidedly moved even faster toward discovering more innovative, focused therapeutic strategies and patient-centric cures to deal with this disease as well as other immunological and neurological disorders.
CureScience™ is a San Diego based 501(c)(3) organization dedicated to developing novel curative therapies through a pre-emptive and personalized approach. At CureScience™, our scientists are evaluating novel technologies involving several modalities, including mesenchymal stem cells (MSCs) for diagnostic and disease mitigation purposes. MSCs have captured the attention of both the scientific and lay media, offering promise of organ repair and regeneration. Achieving clinical applications through the use of stem cells thus far has led to the following achievements:
MSCs have been reported in peer reviewed journals to suppress acute respiratory distress syndrome (ARDS). Preclinical and clinical studies have shown that MSCs work by reversing ARDS caused by other conditions such as influenza virus infection, or sepsis.
The efforts have successfully enabled the treatment of a COVID-19 patient with MSCs recently.
Notwithstanding the foregoing, there is still controversy regarding the safety and efficacy of MSCs in other therapeutic avenues. Hence CureScienceTM is approaching the use of MSCs cautiously and will continue to rigorously evaluate MSCs potential as a diagnostic and therapeutic for various diseases.
Additionally, CureScience™ is evaluating other areas of potential research and development interest, including but not limited to: Use of cerebrospinal fluid (CSF) as an analyte in various neurologic diseases. CSF is a critical component of the human neurological system, and can serve as an important tool in the diagnoses and prognoses of diseases of the nervous system.
Natural killer (NK) cells are innate lymphocytes that represent the first line of defense against tumor cells and viral infections. The CureScience™ team developed novel targeted NK therapies include:
CD19 CAR-NK for Acute lymphocytic leukemia and certain lymphomas
HER2 CAR-NK for breast cancer and gastric cancer
ROR2 CAR-NK for soft tissue sarcomas
Regarding PDL1 CAR-NK, CureScience™ proposes to begin allogeneic NK therapy for the treatment of AML patients. Additionally, it is possible that NK therapy can be combined with clinically available antibody drugs to treat lymphoma and other solid tumors
The foregoing are simply examples of some of the research that we are exploring today. The CureScience™ team has developed an initiative, Accelerated Immunonomics Initiative (AII), to focus on the rapid development of novel therapeutics to address the daunting diseases that afflict us today. We envision the Accelerated Immunonomics Initiative as a novel strategy for early detection, patient specific evaluation and implementation of positive therapeutic outcomes.
Together we will make a difference
Written by Sandeep Pingle, MD, PhD, Scientist
Keywords: CureScience™, ARDS, MFC, CSF
, Personalized Medicine, patient-centric, MSCs, NK, ARDs